Starton Therapeutics
Biotechnology Research • 
Paramus, New Jersey, United States • 11-20 Employees
Company overview
| Headquarters | 215 College Rd, 300, Paramus, New Jersey 07652, US |
| Phone number | +18004495405 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Hematology, Oncology, Transdermal Delivery |
| Founded | 2017 |
| Employees | 11-20 |
| Socials |
Key Contacts at Starton Therapeutics
Amy Chergey
Executive Director, Clinical Operations
Kiriakos Charlie Perperidis
Co-Founder
Starton Therapeutics Email Formats
Starton Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@startontx.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@startontx.com | 66.7% |
{first name}{last name} | johndoe@startontx.com | 33.3% |
About Starton Therapeutics
Starton Therapeutics is a clinical-stage biotechnology platform company that uses proprietary continuous low-dose delivery technology to increase the efficacy and tolerability of approved drugs by maintaining optimal levels of the drug for 24 hrs. a day. Thus, enabling the drugs to ultimately be superior and patients can remain on therapy longer. The company is developing, in parallel, subcutaneous, oral, transdermal, and on-body delivery systems. With multiple delivery methods in development, Starton can expand the number of medicines it is able to deliver continuously, based on patients’ individualized needs and provide multiple avenues for success. Starton’s lead candidate, STAR-LLD, provides a continuous delivery of low-dose lenalidomide (Revlimid®), a drug currently approved for the treatment of adults with multiple myeloma (MM). Despite a good response to lenalidomide, drug-related toxicities remain a challenge that leads to treatment discontinuations. Starton aims to make lenalidomide more effective and tolerable for patients, replacing and expanding the use of Revlimid®. The company is also investigating the use of STAR-LLD in CLL, lymphoma and solid cancers.
Starton Therapeutics revenue & valuation
| Annual revenue | $1,112,215 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,600,000 |
| Total funding | $3,070,900 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Starton Therapeutics has 5 employees across 3 departments.
Departments
Number of employees
Funding Data
Explore Starton Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Starton Therapeutics Tech Stack
Discover the technologies and tools that power Starton Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Form builders
Cookie compliance
JavaScript libraries
JavaScript libraries
CDN
JavaScript libraries
Web servers
Programming languages
Security
Blogs
Analytics
Canada
United Kingdom
France
BelgiumFrequently asked questions
4.8
40,000 users
